VEGFC and lung cancer: Artemisinins have been reported to inhibit tumor lymphangiogenesis by suppression of vascular endothelial growth factor C in a mouse lung cancer cell line [16], block estrogen receptor expression in a human breast cancer cell line [17], and increase calcium levels and activate p38 in a human lung cancer cells [18].